JP Morgan Chase’s Mereo BioPharma MREO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.9K Buy
+21,848
New +$9.38K ﹤0.01% 6827
2025
Q2
Sell
-365
Closed -$821 7437
2025
Q1
$821 Hold
365
﹤0.01% 6652
2024
Q4
$1.28K Hold
365
﹤0.01% 6699
2024
Q3
$1.5K Hold
365
﹤0.01% 6668
2024
Q2
$1.31K Sell
365
-37,757
-99% -$122K ﹤0.01% 6578
2024
Q1
$126K Buy
38,122
+19,004
+99% +$64.3K ﹤0.01% 5567
2023
Q4
$44.2K Sell
19,118
-113,683
-86% -$217K ﹤0.01% 6038
2023
Q3
$171K Sell
132,801
-171,230
-56% -$227K ﹤0.01% 5159
2023
Q2
$401K Sell
304,031
-123,102
-29% -$143K ﹤0.01% 4625
2023
Q1
$302K Buy
427,133
+281,874
+194% +$254K ﹤0.01% 4805
2022
Q4
$77K Buy
145,259
+132,757
+1,062% +$109K ﹤0.01% 5452
2022
Q3
$10K Buy
12,502
+7,922
+173% +$9.69K ﹤0.01% 5965
2022
Q2
$5K Sell
4,580
-8,582
-65% -$6.65K ﹤0.01% 6170
2022
Q1
$15K Buy
13,162
+368
+3% +$476 ﹤0.01% 6128
2021
Q4
$21K Buy
12,794
+9,794
+326% +$19.6K ﹤0.01% 6200
2021
Q3
$7K Buy
+3,000
New +$7.94K ﹤0.01% 6213

Other funds holding MREO

JP Morgan Chase's MREO Position: Q1 2026 in Review

JP Morgan Chase opened a new position in Mereo BioPharma (MREO) in Q1 2026: 21,848 shares worth $6.9K. The stake represents ﹤0.01% of the portfolio and ranks #6827 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in MREO as recently as Q1 2025.

JP Morgan Chase first reported a position in MREO in Q3 2021 and has held it in 16 quarters since. The position peaked at $401K in Q2 2023. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • JP Morgan Chase held 21,848 shares of Mereo BioPharma worth $6.9K as of Q1 2026.
  • Mereo BioPharma was a new JP Morgan Chase position in Q1 2026.
  • Mereo BioPharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6827 holding.
  • JP Morgan Chase first reported a position in Mereo BioPharma in Q3 2021 and has held it in 16 quarters since.
  • JP Morgan Chase's Mereo BioPharma position peaked at $401K in Q2 2023.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.